FDA Greenlights Imaging Agent to Detect Residual Cancer After Lumpectomy

(MedPage Today) -- The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the Lumicell Direct Visualization...
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news